Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (181-190 of 386) with videos related to

Pageof 39
Sort By:
World Journal of Gastroenterology|December 7, 2016
New real-time-PCR method to identify single point mutations in hepatitis C virusQian Chen, Irene Belmonte, Maria Buti, et al.
Hepatology Communications|January 8, 2020
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis BAnna S Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.
Gastroenterology|September 27, 2013
Telbivudine improves renal function in patients with chronic hepatitis BEdward J Gane, Gilbert Deray, Yun-Fan Liaw, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2019
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trialsMaria Buti, David K Wong, Edward Gane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2014
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of EgyptDorothée Obach, Sylvie Deuffic-Burban, Gamal Esmat, et al.
Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.
Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Pageof 39

Showing results (181-190 of 386) with videos related to

Sort By:
Pageof 39
World Journal of Gastroenterology|December 7, 2016
New real-time-PCR method to identify single point mutations in hepatitis C virusQian Chen, Irene Belmonte, Maria Buti, et al.
Hepatology Communications|January 8, 2020
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis BAnna S Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.
Gastroenterology|September 27, 2013
Telbivudine improves renal function in patients with chronic hepatitis BEdward J Gane, Gilbert Deray, Yun-Fan Liaw, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2019
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trialsMaria Buti, David K Wong, Edward Gane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2014
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of EgyptDorothée Obach, Sylvie Deuffic-Burban, Gamal Esmat, et al.
Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.
Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Pageof 39